Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about preliminary interim results from the company’s SLAB clinical trial in aged dogs.
Leire explained that the SLAB trial is a randomised, blinded clinical study involving 24 dogs. The analysis remains preliminary, with the trial ongoing, but Leire said the strength and consistency of the early signals were unexpected.
The interim results showed that every treatment group outperformed the control group across multiple endpoints, including survival, muscle mass, frailty and quality of life. Leire emphasised that although the sample size is small - six dogs per arm - the consistency of outcomes across endpoints is meaningful in a rigorous clinical setting. As he explained, “such a consistency across endpoint in a small sample is often a very encouraging early sign.”
Importantly, the study reported zero adverse events, reinforcing the therapy’s safety and tolerability profile at this stage. The trial will continue for a further 90 days following the dosing period to assess the durability of effect. Additional data still to come include methylation clock analysis, which measures biological age at the molecular level, and comprehensive muscle biopsy histology.
Leire said the interim data is already strengthening partnership discussions within the animal health sector, noting that randomised clinical data shifts conversations significantly. While remaining appropriately cautious, he added that “the risk reward at this stage is interesting” for investors.
For more interviews and market insights, visit Proactive’s YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates.
#GenflowBiosciences #DrEricLeire #BiotechStocks #ClinicalTrials #LongevityResearch #AnimalHealth #Biotechnology #InvestorNews #LifeSciences #AgingResearch
